Ldb 145 geni mutanti_2014-11-07 franchini - marketing e trasferimento tecnologico

TTFactor @ Laboratori dal Basso
Jacopo Franchini, Business Development Manager
TTFactor S.r.l.
Laboratori dal Basso “Geni Mutanti”
Campus Ecotkne - Lecce
7 November 2014
“Dalla Ricerca al prodotto, dal prodotto al
Mercato”

1.  Doing
Technology
Transfer
for
3
research
center
in
Milano

-‐  IEO
-‐
IFOM
-‐
Monzino

2.  Why
should
industry
and
academia
collaborate?

3.  TTFactor
in
this
context
:
A
Tech
Transfer
Company

4.  Career
development
session

INDEX

•  European
InsLtute
of
Oncology
(IEO)

•  FIRC
InsLtute
of
Molecular
Oncology
(IFOM)

•  Centro
Cardiologico
Monzino

1.  Doing
Technology
Transfer
for..

•  Founded
in
1994,
as
a
Comprehensive
Cancer
Center

•  Private
company
owned
by
the
major
Italian
Banks
and
Insurances,

part
of
the
Na>onal
Health
System
(IRCSS)

The
Main
Actors
(1)

• The
European
Ins>tute
of
Oncology
•  Clinical
Cancer
Center
•  Research
Laboratories

•  Founded
in
1999,
as
a
Reaseach
InsLtute
focused
on
Basic
Cancer

Research

•  Founda>on,
owned
by
FIRC,
the
largest
cancer-‐research
Italian
charity

The
Main
Actors
(2)

• The
FIRC
Ins>tute
of
Molecular
Oncology

The
Main
Actors
(3)

• The
Campus
IFOM-‐IEO
Together,
Ifom
and
Ieo,
Founded
the
campus

to
expand,
integrate

their
research
acBviBes
and
to
exploit
the
resultant
synergies:

Ø  Virtual
ins>tu>on;
Common
Facili>es
(imaging,
proteomic,

genomic
etc.)
scien>ﬁc
governance
entrusted
to
the
Scien>ﬁc

Directors
of
IEO
and
IFOM;
common
policies.

•  Part
of
IEO’s
group
Founded
in
1981
and
IRCCS
since
1992

•  Private
Hospital
owned
by
IEO
and
part
of
the
Na>onal
Health
System

(IRCSS)

•  THE
ONLY
RESEARCH
HOSPITAL
IN
EUROPE
EXCLUSIVELY

DEVOTED
TO
THE
TREATMENT
OF
CARDIOVASCULAR

DISEASES

•  1ST
RANKED
FOR
CARDIO-‐VASCULAR
SURGERY
RESULTS
BY

THE
ITALIAN
MINISTRY
OF
HEALTH

•  MAJOR
TRANSLATIONAL
RESEARCH
PROGRAMS
AT
CCM:

1.  BIOLOGY
AND
BIOCHEMISTRY
OF
ATHEROTHROMBOSIS

2.  VASCULAR
BIOLOGY
AND
REGENERATIVE
MEDICINE

3.  IMMUNOLOGY
AND
FUNCTIONAL
GENOMICS
OF
THE
PLAQUE

4.  CARDIOVASCULAR
TISSUE
ENGINEERING

….
And
Centro
Cardiologico
Monzino

TTFactor @ Bocconi
The
IEO
Clinical
Center

1400
Clinics

The
IFOM-‐IEO
Campus

450
Researchers

40

Research
Groups

130
PhD
Students
(SEMM)

150
Post-‐Docs

50
Scien>sts/Technicians
(Scien>ﬁc
Groups)

80
Scien>sts/Technicians
(Cogentech)

Centro
Cardiologico
Monzino

644
Clinics

60
Research

The
Main
actors
(4):
People
involved

TTFactor @ Bocconi
The
IFOM-‐IEO
Campus

To
adopt
an
approach
driven
by
scienLfic

curiosity
and
strongly
based
on
fundamental

biology

The
IEO
Clinical
Center

To
provide
the
academic

home
and
integrated

resources
to
advance
clinical

science

• To
favor
and
accelerate
transfer
of
knowledge
for
cancer
preven>on
and

treatment

• To
build
on
the
value
of
scien>fic
research
with
a
strictly
non-‐profit

research

Vision

Main
drivers:

•  To
increase
R&D
produc0vity;

•  To
share
the
development
costs/risks
with
a
commercial

partner;

•  To
advance
clinical
science
for
pa3ent
benefit;

•  To
find
new
medical
solu3ons
based
on
scien3fic
results;

2)
Why
should
industry
and
academia

collaborate?

Discovery
Phase I
FDA Review/
Approval
Additional post-
marketing tests
Phase III
Phase II
Preclinical Tests
Target Discovery
Target Validation
(2-10 Years)
Test in lab and animal models
20-80 patients; safety and Max Tollerated Dose
(MTD)
100-300 patients: efficacy and side effects
1000-1500 patients: adverse events; overall survival
MARKET
LAUNCH
The
Long
journey
from
R&D
to
the
Market

Stage

Discovery

Pre-‐clinical

Clinical

Fda/
Emea

Marke>ng
Approval

Time

2-‐10
yrs

2-‐3
yrs

4-‐6
yrs

1-‐2
yrs

Compound

Success
Rate

10,000

250

10

1

Total
Time:
12
years

Total
investment:
800-‐900
Mln
Euro

20
years
patent
life
-‐
Time2Mkt
=
Short
Exclusivity

Drug
Development:
it
is
a
long
process

Success
rates
from
ﬁrst-‐in-‐man
to
registra>on

[Data
from
the
ten
biggest
drug
companies
1991–2000]

Less
than
1
in
50
early
drug
discovery
projects
end
with
a
drug
in
the

market

•  DISCOVERY:
cumula>ve
aari>on
is
~
80%;

~
1
in
5
projects
gets
as
far
as
selec>ng
a
compound
for
clinical
trials

•  DEVELOPMENT:
aari>on
between
selec>ng
a
compound
and
marke>ng
is
~
90%;

~
1
in
10
projects
reach
the
market

High
akriLon
rate
and
risk
of
failure

Why
compounds
fail
in
development?

•  ñRegulatory
requirements
–
(efficacy
and
safety)

•  Targe>ng
(profitable)
indica>ons:
rare
disease
or
chronic

•  Restric>on
in
reimbursement
by
na>onal
healthcare
authori>es

•  Too
much
manager
and
few
science
(CEOs
with
no
scien>fic

background)

•  Pressures
for
fast
returns
by
shareholders

•  Conformism
(benchmarking
mania
on
targets
and
technology)

•  Merger
mania
(during
past
five
years,
top
ten
pharma
have
eliminated

more
than
200,000
jobs)

•  The
end
of
Blockbuster
era
/
focus
on
rare
disease
(one
shot
treatment

at
higher
price)

Industry
R&D
spending
is
growing
vs
low

producLvity
and
lack
of
innovaLon

• 
Lack
of
understanding
of
complex
disease
biology

• 
Lack
of
accurate
and
efficient
methods
for
target
idenLficaLon/
validaLon

• 
Lack
of
“conLnous
validaLon
process”
of
the
targets
(Basic

research
and
following
target’s
valida>on
ojen
not
closely

connected)

• 
Lack
of
accurate
and
efficient
methods
for
paLent
straLficaLon

This
is
why
science
is
key!!!

Boklenecks
in
drug
discovery/development:

“…erosion in confidence in the industry and its products …
…may be moving closer to a pharmaceutical ‘ice age’ and the
potential extinction of the industry, at least as it exists today…”
“…Wall Street and consultants argue that shareholders will be best served
by Big Pharma ending all early-stage drug research entirely..
due to limits on their internal capacity to innovate ……to license in new
compounds from smaller biotech-style companies, or from academia…“
report from analysts at Morgan Stanley-Financial Times Feb 1,2010
Nature Rev. Drug Discov. 9, 203 (2010)
•  Industry
R&D
spending
is
growing

vs
low
producLvity
and
lack
of
innovaLon

•  The
socio-‐economic
demand
and
high
failures
rate
are
forcing
pharma
industry
to

reassess
R&D
strategies
to
improve
eﬃciency
and
producLvity

•  The
pharmaceuLcal
industry
is
currently
embracing
unprecedented
levels
of

change

The
result?
An
high
need
for
collaboraLon

•  Reduc>on
of
public
funds
for
research

•  Absence
of
speciﬁc
funds
dedicated
to
pre-‐clinical
and

clinical
development
(TRANSLATIONAL
RESEARCH)

•  GlobalizaLon
of
the
compeLLon
for
na>onal
&

interna>onal
resources

•  Emergence
of
new
scienLﬁc
paradigm

(biotechnologies)vs
the
conven>onal
pharma
R&D

(chemistry)

Partnership
with
Pharma:
key
driver
for
the

Academia
and
vice
versa

•  Licensing
revenues

•  Start-‐up
crea>on

GeneraLng
new
funding
sources

•  Favor
translaLonal
research
(absence
of
speciﬁc

funds
dedicated
to
pre-‐clinical
and
clinical

development)

•  Be
akracLve
for
pa>ents
by
oﬀering
innova>ve

therapeu>c
solu>ons
(trial
of
new
drugs)

Compete
at
the
global
level

HIV
Treatment:
EMTRIVA

1990:
first
patent
filed
by
Emory
University,
Atlanta

1996:
licensed
to
Triangle
pharmaceu>cals

2003:
approved
by
FDA
and
commercialized
by
Gilead

Sciences

Cancer
(glioma):
Temodal®,Temozolomide

1980s:
developed
by
Cancer
Research
UK

1990s:
licensed
to
Schering-‐Plough.

2007:
approved
by
NICE
for
brain
tumors

MulLple
Sclerosis:
COPAXONE

1971:
first
Patent
filed
by
Yeda
(TTCompany

Weizmann
Ins>tute
Israel).

1987:
licensed
to
Teva
PharmaceuLcals
Ltd.

1996:
approved
by
FDA

From
Academia
to
Market

NASDAQ
Biotechnology
Index
(^NBI)
-‐
NASDAQ
-‐
DOW-‐JONES

The
Biotech
Market

Jazz
Pharmaceu>cals
buys
the
Italian
rare-‐disease
drug
developer

Gen>um
for
1
Billion
USD

Intercept
shares
at
Nasdaq
has
rocketed
from
70
to
450
dollars
in
a
single
day
(10
January)

250
Mln
€

Okairos
is
developing
the
ﬁrst
Ebola
vaccine

Biotech
in
Italy:
a
great
opportunity

Tra
le
15
biotech
piu
promeaen>
(Fierce
Biotech)

Esempio
virtuoso
di

tech
transfer
salen>no
(2006)

The

“Death
Valley”

Industry
Academia
Diﬃcult
to
build
a
“safe
road”
from
research

to
market

Academic

Research

Centers

Pharma

Biotech

Academic

Hospitals

Target
Iden>ﬁca>on

Drug
Discovery,

Development,

Market

Clinical
Development

The
LIMIT:
disease
mechanisms’
knowledge
is
limited
at
the

academic
stage

The
current
model:
a
segmented
process

Provides
the
Know-‐how

on
drug
development

Pharmas

and

Biotechs

Provides
the
Know-‐how

on
disease-‐mechanisms

Academic

Research

Centers
Provides
the
scien>ﬁc

and
clinical
ra>onale

for
the
drug

Hospitals

The
advantage:
disease
mechanisms’
knowledge
pervades

the
en>re
process,
interac>on
is
a
key
for
success

Provides
rules
for

protec>on
of
pa>ents
Local

Governments

The
ideal
model:
integraLon
to
create
value

Which
are
the
challenges?

Ø  What
is
changing?

From
the
sole
figure
of
the
business
angel
inclined

to
fund
early
stage

projects,
new
financial
tools
are
emerging:

•  increasing
presence
of
Corporate
Venture
Capital
(i.e.
Novar>s,
J&J,
Roche,

Bayer)

•  Seed
investments
funds
directly
owned
by
universi>es’
technology
transfer

offices
(
Imperial
Innova>ons,
Karolinska
Investment
FUND
I,
Momentum

Fund
Tel
Aviv
University
…)

•  Open
innovaLon
models
to
foster
the
innova>ve
performance
of
the
big

corporates
(
GSK
DPAC
-‐
BAYER
-‐
NOVARTIS
BioCamp
-‐
J&J
Innova>on)

•  Achieve
a
change
in
the
researchers’
culture
and
approach

to
science:
aiming
also
to
reach
pa>ents
through
applied

research

•  Thinking
long
term
(tech
transfer
return
in
5-‐10
year)

•  Working
together
(management/scien>sts/clinicians
each

focusing
on
its
task)
to
reach
common
objec>ves

•  Addressing
complexity
earlier:
collabora>ons
with

Universi>es
and
Professor
aﬃlia>ons
(i.e.
we
have

agreement

Universita
di
Milano,
Is>tuto
Italiano
di

Tecnologia,
Universita’
di
Pisa,
Universita’
di
Pavia…)

Which
are
the
challenges?

TTOFFICE

ADMINISTRATION

• 
low
costs

• 
revenues

• 
control/burocracy

RESEARCHERS

• 
services

• 
patents

• 
publica>ons

DEAN
OF
RESEARCH

• 
services

• 
freedom
of
research

• 
poli>cs

COMPANIES
AND
VC

• 
efficiency

• 
speed

• 
authority

Why
TT
offices
are
(parLally)
ineffecLve

A
new
vision
of
the
Technology

Transfer
to
allow
the
integraLon

BASIC
MODEL:

–  Technology
Transfer
(“Tech
Transfer
1.0”)

“The
IFOM-‐IEO
MODEL”:

–  Technology
Development
(“Tech
Transfer
2.0”)

TTCOMPANY

SHAREHOLDERS

-‐President

-‐Board
of
Directors

MISSION

OBJECTIVES

GOALS

COMPANIES
AND
VCs

-‐eﬃciency

-‐speed

-‐authority

The
importance
of
being
a
company

Biotech/
Pharma
Target
Validation
Target ID
Hit identif.
Hit to lead
Lead opt.
Preclin. Dev.
Clinical trials
Academy
Tech Transfer 1.0 The IFOM /IEO model
Academy Biotech/
Pharma
PARTNERING
AT
LATER
STAGE,
A
DE-‐RISKED
MOLECULE

TTFACTOR

Our
vision
of
Drug
Discovery
Process

•  Self funded “industry-skilled” small molecule program;
•  Science driven target identification and validation integrated with drug
discovery efforts
•  Targeting cancer’s “hottests targets”
•  Major collaboration with MD Anderson Applied Cancer Institute in epigenetics
IEO
Drug
Discovery
Program
(DDP)

•  a
technology
transfer
company
owned
by
IFOM
and
IEO

•  exclusive
licensee
of
all
IEO’s
and
IFOM’s
IP
rights

•  with
exclusive
right
to
nego>ate
and
sign
contracts
with
THE

FOR
PROFIT
SECTOR
in
name
and
on
behalf
of
IFOM
and
IEO

•  Exclusive
consultants
Centro
Cardiologico
Monzino

One
step
to
decision
and
execuLon
in
all
makers
related
to

IP
exploitaLon

TTFactor’s
corporate
backbone


Key
“TT”
FACTORs

•  A
Company
facing
Companies…

A
light
structure
allowing
a
>me
eﬀec>ve
decision
process
and
an

eﬃcient
management
of
the
nego>a>on

•  An
interna>onal
Board
of
Directors

To
take
the
advantage
of
years
of
succesful
experience
in

technology
transfer
(improved
learning
curve)

•  Bring
science
to
Market

A
strategic
Business
Development
Advisory
Board
to
help

tailoring
the
market
proposal
for
each
project

Pier
Giuseppe
Pelicci,
President
-‐
IEO

Claudio
Basilico
-‐
New
York
University

Leonardo
Biondi
-‐
IFOM

Mario
Cesana
-‐
IEO

Andrea
Cuomo
-‐
ST
Microelectronics

Marco
Foiani
-‐
IFOM

Isaac
Kohlberg
-‐
Harvard
University

Tomas
Lindhal
-‐
Cancer
Research
UK

Elisabeaa
Petrucci
-‐
FIRC

Domenico
Triarico
-‐
IEO

Daniela
Bellomo,
Managing
director

Marzia
Fumagalli,
Intellectual
Property

Jacopo
Franchini,
Business
Development

Giulia
Negri,
Marke3ng

Barbara
Gallone,
Assistant

Team
Board
of
Directors

Team
and
Board
of
Directors

Giulio
Draeaa,
MDACC

Isaac
Kohlberg,
Harvard
University

Nagesh
Mahantappa,
CEO
Scholar
Rock

Kazumi
Shiosaki,
MPM
Capital

Katherine
Turner,

Scholar
Rock

Business
Advisors

How
do
we
operate?

abandon

more
data
needed

abandon

•  Novelty search
•  Market search
•  Manageability
Feedback
from
Companies

Business
Development
Advisory
Board

Develop
Further

(Internally
or
via
Spin
oﬀ)

License

Patent
porsolio

In-‐licensing
+

abandon

InvenLons

13

TTFactor Method of antigen loading
for immunotherapy
IFOM-IEO-Campus, Milan, Italy
Lastupdate02.2011
duction is in preparation for Phase I;
the clinical trial in melanoma patients
is planned for June-July 2011.
Applicability
New method to generate potent DC-based
tumor vaccines
• Adjuvant treatment (to elimate mini-
mal residual disease) for the moment in
melanoma but it can be extended to other
diseases
• Metastatic melanoma
The European Institute of Oncology (IEO)
is available for clinical support, hosting
several studies on melanoma.
Opportunity
We are looking to partner this program for
further development with companies in
immuno-therapeutics and tumor vaccine.
References
Saccheri F. et al. Bacteria-induced gap
junctions in tumors favor antigen cross-
presentation and antitumor immunity. Sci
Transl Med. 2010 Aug 11; 2(44): 44ra57.
Avogadri, F., et al.. Eur. J. Immunol. 2008
Jul;38(7):1937-47.
Patent Applications
US 61/370,599
TTFactor (Srl)
Via Adamello, 16
20139 Milan (Italy)
Germano Ferrari PhD, MBA
Business Development Manager
T +39 02 94375.140
E germano.ferrari@ttfactor.com
W www.ttfactor.com
Introduction
Dendritic cells (DCs) are key players in the
activation of T cells. DCs are endowed
with the ability to present exogenous
antigens that have not been generated
within DCs for the activation of T cells, via
the cross-presentation pathway. Cross-
presentation is required for the initiation
of effective anti-tumor T cell responses
and the repertoire of presented peptides is
crucial to activate T cells that will recognize
and kill tumor cells. However, the antigen
presentation machinery, and in particular
the proteasome, differs between tumor
cells and DCs. A major drawback is that
DCs could process and present peptides
that are different from those presented by
tumor cells, thus initiating a tumor-specific
response that will not recognize the tumor.
Brief description
We show that bacteria can be successfully
used to induce tumor to DC communica-
tion via gap-Junctions allowing cross-pre-
sentation of tumor antigens and effective
activation of tumor specific immune re-
sponses. Salmonella typhimurium infection
facilitates the cross-presentation of tumor
antigens and its exploitation can generate
potent DC-based tumor vaccines.
Thus, we have developed a new
method of antigen cross presentation
for immunotherapy, that has proven
very effective in mice (see figure).
Mice vaccinated with DCs loaded with
bacteria-treated tumor cells are fully
protected against challenge with the
highly aggressive B16 melanoma. This
mechanism has been confirmed on hu-
man cells in vitro and is under in vivo
validation. The protocol for GMP pro-
2.
Prior
art
&
Market
intelligence
5.
Find
partner
and
make
the
deal

1.
IP
culture
&
new
inven>ons
3.
Filed
patent
applica>on
4.
Promote
it
and

Publish

39
•  Cash-‐in
at
sign
(upfront)

•  Cash-‐in
when
reaching
development
goals
(milestones)

•  Cash-‐in
once
on
the
market
(royal>es
on
sales)

MARKET
-‐
PATIENTs

Research
Institution
Company
Right
(development,
marke3ng,
distribu3on)

Upfront
+
milestones
Royalties (% on sales)
A
way
to
ﬁnance
the
Research
Ins>tu>on
and
get
the
commitment
from

the
developer
(industrial
partner)

•  Cash-‐in
at
sign
(upfront)

•  Cash-‐in
when
reaching
development
goals
(milestones)

•  Cash-‐in
once
on
the
market
(royal>es
on
sales)

What
does
a
licensing
agreement
mean?

PROJECT
SOURCE
IP
DISCOVERY
PRECLINIC
CLINIC

PARTNERED

uPAR
ANTAGONISTs
&
BIOMARKERs
IFOM
✔
LDH
INHIBITORS
IEO
✔
mPTP
INHIBITORS
IEO/GNX
✔
HDAC
INHIBITOR
IEO/GNX
✔
miRNA
DIAGNOSTIC
TEST
IFOM/IEO
✔
STEM
CELL
SIGNATURE
IFOM/IEO

LSD-‐1
INHIBITORS

IEO
✔
AVAILABLE
FOR
PARTNERING
IN
ONCOLOGY

RADIO-‐PHARMACEUTICALS
ST/IEO
✔
NON
CODING
RNA
(DDRNA)
IFOM
✔
TARGET
ID&VALIDATION

IEO

scFv
ANTIBODIES
TARGETING
TUMORs
IEO

AVAILABLE
FOR
PARTNERING
IN
OTHER
INDICATIONS

SHORT
TSLP
PEPTIDE
IEO
✔
BACTERIAL/PROBIOTIC
PLATFORM
IEO
✔
BETA-‐CATENIN
INHIBITORS
IFOM
✔
GPR17
MODULATORS
CCM
✔
iPS
GENERATION
FACTOR
IFOM
✔
SMARTFOOD
IEO

PATIENT
DISEASE
MODEL
/
DRUG
SCREENING
IEO

STROKE
(HEARTH/BRAIN)

PARTNERED
ONCOLOGY

PARTNERED
CANCER
Epigene>cS

IMMUNOTHERAPY

ONCOLOGY/AGEING

PARTNERED
ONCOLOGY

PARTNERED
DERMATOLOGY

HEART
DISEASE

PARTNERED
LUNG
CANCER

INFLAMMATION
(IBD)

BRAIN
RARE
NGIOMA

✖
BREAST
CANCER

IART-‐BREAST
CANCER

NEGOTIATION

NUTRITION
&
SCIENCE

Biotech
&
VC

Biotech
&
VC

PARTNERED

PARTNERED

AGGRESSIVE
TUMORs

AGGRESSIVE
TUMORs

REGEN.
MEDICINE

AUTISM
&
WILLIAMS

A
growing
pipeline

•  104
invenLon
disclosures
from
scien>sts
16
new

patent
families
and
2
trademarks
-‐
7
in-‐licensed

patent
families

•  190
contracts
with
biotech/pharma/food

companies,
and
selected
Academic
InsLtuLons

•  80
Non
Disclosure
Agreements
including
GSK,
J&J

Roche,
Novar>s
etc

•  9
license
and/or
co-‐development
with
European

investment
ﬁrms
and
companies

•  a
major
alliance
on
drug
discovery
for
epigene>c

targets
with
MDACC

Food
Academia
Pharma &
BIOTECH
In
FOUR
years

A
solid
track
record

In
TTFactor
we
aim
not
only
to
collect

the

but
also
to

culLvate
the
tree.

There
are
several
models
of
Tech
Transfer,
more
or
less
ac>ve

towards
the
market
depending
on
the
features
and
voca>on
of
the

model
chosen.

IFOM
and
IEO
have
invested
in
a
innova>ve
model
of
technology

transfer
in
the
Italian
landscape:

A
simple
organiza>on,
comparable
on
one
hand
to
the
industrial

world
and
able,
on
the
other
one,
to
adapt
itself
to
IEO
and
IFOM

strategies
in
R&D

Conclusion

4.
Career
Development
Session

VIDEO INTERVISTA SUL WORKSHOP
TTFACTOR
Speakers:!
•  Gianmario Verona,
Vice Rector of Faculty, SDA Bocconi
outgoing Director MBA!
•  Federica Draghi,
Business Development Director, Genextra!
•  Rocco Paracchini,
Senior Manager Global Sales, Aptalis
Pharma!
•  Olga Capasso,
Patent Attorney, De Simone & Partners!
•  Marzia Fumagalli,
Intellectual Property Manager, TTFactor!
•  Antonino Amato,
Director Clinical Trial Center, Policlinico
Gemelli!
•  Marco Morello,
Manager Healthcare & Life Science
Division, PageGroup!
!
!
!
Moderator:!
•  Daniela Bellomo,!
Founder and Managing Director, TTFactor!
Agenda:!
14.00 "Registration"
"
14.30 "Round Table 1!
"
"Careers in ﬁnance, investment,
!corporate business development !
"G.Verona, F.Draghi, R.Paracchini!
!
!Recent experiences from your peers"
"E.Beltrami, J.Sgualdino, N.Bacchi!
!
15.40 "Q&A"
"
15.50 "Coffee Break!
!
16.15 !Round Table 2!
!!
!Careers in intellectual property, !
!tech transfer, regulatory & drug safety!
!O.Capasso, M.Fumagalli, A.Amato!
!!
!A look at the Italian
!healthcare job market and hints
!on how to make a CV appealing !
!M.Morello!
!
17.20 !Q&A and meeting end"
Looking beyond the lab
Workshop on career opportunities
for qualified scientists
21 October 2014
Campus IFOM-IEO, Conference Room, Bldg. 9
IN COLLABORATION WITH:ORGANIZED BY:
Follow TTFactor on:
#lookingbeyondthelab

Jacopo Franchini, MSc
Business development & marketing Manager
•  Prior
joining
TTFactor,
Jacopo
was
Sales
Area
Manager
for
INDIA
and

MENA
regions
at
Solmag-‐Olon,
an
API
manufacturer.

•  Previously
he
served
as
Contract
Coordinator
in
the
Business

Development
unit
of
MolMed
S.p.A
(MLM.MI),
a
Biotech
Company

focused
on
oncology.

•  Internship
at
King’s
College
Business
London
Ltd,
the
tech
transfer

company
of
a
major
university
in
UK.

•  Jacopo
holds
a
Master
degree
in
Pharmaceu>cal
Biotechnology
from

Vita
Salute
San
Raﬀaele
University
and
he
aaended
diﬀerent
post

graduate
courses
on
patent
management
and
business

development:

–  MIP
Corporate
Master
Program
in
Accoun>ng
and
Financial
statements;

–  Intellectual
Property
and
patents
post
graduate
course
at
Universita’
di
Pavia;

–  Business
development
course
and
licensing
at
Assobiotec
Milano

Marzia Fumagalli, PhD, LLM
Intellectual Property Manager
•  Marzia Fumagalli joined TTFactor in 2011, after having
collaborated with the Company since 2010.
•  She holds an LLM (Master of Laws) in IP Law and
Management (MIPLM) from CEIPI, Center for International
Intellectual Property Studies, of University of Strasbourg.
•  Prior joining to TTFactor, she was a postdoctoral research
fellow in biomedical oncology at IFOM (The FIRC Institute
of Molecular Oncology Foundation).
•  Marzia obtained her PhD in Molecular Medicine from
SEMM, the European School of Molecular Medicine, and
she holds a Master Degree in Medical Biotechnology from
University of Milan


CV

• Founder
and
current
Managing
Director
of
TTFactor
Srl
(Milan)
since
2010

• Director
Technology
Transfer
Office
at
San
Raffaele
Hospital
(Milan)
2002-‐2010

• Mater
Business
AadministraLon
at
University
of
Queensland
Business
School

• Senior
Officer
at
IMBcom
(TTO
-‐
University
of
Queensland)
2001-‐2002

• Post
Doc
at
Queensland
InsLtute
for
Medical
Research
(Australia)
1996-‐2000

• PhD
student
at
St
Georges’
Hospital
Medical
School
(London,
UK)
1992-‐1996

Other:.

Member
of
the
Board
of
Directors
of
the
Parco
Tecnologico
Padano
(www.technoparco.org),

Italy’s
largest
scien>fic
park
dedicated
to
the
agri-‐food
sector
by
nominaLon
by
the
Mayor
of

Milan

Daniela Bellomo, PhD, MBA
Direttore Generale TTFactor

Daniela Bellomo, Managing director
Marzia Fumagalli, Intellectual Property
Jacopo Franchini, Business Development
Giulia Negri, Marketing
Barbara Gallone, Assistant
What
I
like
the
most
of
my
job
and
which
are
the
challenges…

Every
day
I
learn

something
new

both
from
science

and
from
business

You need both an eye for
details and an open mind
for the big picture
I enjoy working in a
nimble ad streamlined
team with clear
objectives
It is hard to estimate
the value of an early
technology still far
away from the
market
It gives me a cross view
of science
We have to keep
everyone’s
expectations realistic
I love exploring the
unknown and being part of
discoveries that will
contribute to new
therapies
You
work
under

pressure,
managing

many
diﬀerent
tasks

whilst
respec3ng

deadlines

If
you
wish
to
learn
more..

Tech
Transfer:

AUTM
(hap://www.autm.net/)

Associa>on
of
University
Technology
Managers

ProTon
(hap://www.protoneurope.org/)

European
Associa>on
for
Knowledge
Transfer

Netval
(hap://www.netval.it/)

Network
for
the
valorisa>on
of
the
University

Italian
research

Intellectual
Property
and
Patents:

EPO
(hap://www.epo.org/)

European
Patent
Oﬃce

WIPO
(hap://www.wipo.int/about-‐ip/en/iprm/)

World
Intellectual
Property
Organiza>on

CEIPI
(hap://www.ceipi.edu/)
at
Univ
of
Strasbourg

Centre
d'Etudes
Interna>onales
de
la
Propriete

Intellectuelle

www.vactor.com

Follow
us
on

@TTFactor

Ldb 145 geni mutanti_2014-11-07 franchini - marketing e trasferimento tecnologico

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (18)

Semelhante a Ldb 145 geni mutanti_2014-11-07 franchini - marketing e trasferimento tecnologico

Semelhante a Ldb 145 geni mutanti_2014-11-07 franchini - marketing e trasferimento tecnologico (20)

Mais de laboratoridalbasso

Mais de laboratoridalbasso (20)

Último

Último (17)

Ldb 145 geni mutanti_2014-11-07 franchini - marketing e trasferimento tecnologico